Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of lutetium (177Lu) oxodotreotide with F-1520 in somatostatin receptor-positive progressive neuroendocrine tumors
jRCT2080223813Phase 2Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Feb 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate and lysine hydrochloride + arginine hydrochloride in apudoma (NET) and midgut carcinoid tumor, sponsored by FUJIFILM Toyama Chemical. Started Feb 2018; status: completed.
02
Drugs
lutetium Lu 177 dotatatelysine hydrochloride + arginine hydrochloride
03
Conditions
apudoma (NET)midgut carcinoid tumor
Beyond the preview
Go deeper on jRCT2080223813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223813.